<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220412054516N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-08</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of Caine P with topical benzocaine on reducing needle entry pain in palatal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>A Comparison study of the effects of Caine P with topical benzocaine in reducing needle insertion pain in Palatal anesthesia in children 9 to 12 years</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>23</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62925</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: After selecting the samples with inclusion criteria and without exclusion criteria, the quadrants were divided into two groups by blocking method. Randomization was performed with Random allocation software. Based on this, 23 double blocks were created with the mentioned software and provided to the main executor, Blinding description: The patient and the dentist performing the treatment do not know which anesthesia was applied on which side.</study_design>
      <phase>3</phase>
      <hc_freetext>Needle entry pain before palatal anesthesia injection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: quadrant receiving Caine P as local anesthesia before injection = with a cotton swab on one side of the jaw Caine P (2.5% lidocaine cream and 2.5% perilocaine similar to EMLA, product of IranNajo) will be applied by the injector. Injection will be done 5 minutes after local anesthesia with 2% lidocaine (manufactured by Daru Pakhsh) with a 30 gauge needle (manufactured by DENJECT) in a 3 mm area of ​​the free gingival margin and that the needle's bevel is facing the bone, and the needle goes inside the tissue till it is in contact with bone. The injection is given to achieve palatal anesthesia. After the injection, the VAS scale is shown to the patient to indicate the amount of pain. Measurements with the VAS will be performed only once per session. The average of these numbers will be recorded and the data will be analyzed. Intervention 2: Control group: quadrant receiving Benzocaine as local anesthesia before injection = with a cotton swab on one side of the jaw benzocaine (20% benzocaine gel from Master dent) will be applied by the injector. Injection will be done 5 minutes after local anesthesia with 2% lidocaine (manufactured by Daru Pakhsh) with a 30 gauge needle (manufactured by DENJECT) in a 3 mm area of ​​the free gingival margin and that the needle's bevel is facing the bone, and the needle goes inside the tissue till it is in contact with bone. The injection is given to achieve palatal anesthesia. After the injection, the VAS scale is shown to the patient to indicate the amount of pain. Measurements with the VAS will be performed only once per session. The average of these numbers will be recorded and the data will be analyzed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as information about the main outcome or the like, can be shared

When:
Access period starts 6 months after the results are published

To whom:
Study documents will be available only to researchers working in academic and scientific institutions

Conditions:
The use of data to carry out new research projects is permitted

Where to obtain:
To the e-mail address of the respondent, Mostafa Akbari:
mostafa.akbari@mazums.ac.ir

How to obtain:
After reviewing the incoming emails, the data will be sent to the applicant.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehdi Taghian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Office Unit 610, 6th Floor, Shahriar 3 Building, Farhang St, Sari</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>-</zip>
        <telephone>+98 11 3330 5443</telephone>
        <email>m.taghian@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehdi Taghian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Office Unit 610, 6th Floor, Shahriar 3 Building, Farhang St, Sari</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>-</zip>
        <telephone>+98 11 3330 5443</telephone>
        <email>m.taghian@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children 9 to 12 years
Children who need palatal anesthesia injections on both sides of the jaw
Written consent was obtained from their parents
They are cooperative
They are systemically healthy</inclusion_criteria>
      <agemin>9 years</agemin>
      <agemax>12 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>At risk for Methemoglobinemia
Allergic to benzocaine, lidocaine and prilocaine</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y65.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other specified misadventures during surgical and medical care</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: quadrant receiving Caine P as local anesthesia before injection = with a cotton swab on one side of the jaw Caine P (2.5% lidocaine cream and 2.5% perilocaine similar to EMLA, product of IranNajo) will be applied by the injector. Injection will be done 5 minutes after local anesthesia with 2% lidocaine (manufactured by Daru Pakhsh) with a 30 gauge needle (manufactured by DENJECT) in a 3 mm area of ​​the free gingival margin and that the needle's bevel is facing the bone, and the needle goes inside the tissue till it is in contact with bone. The injection is given to achieve palatal anesthesia. After the injection, the VAS scale is shown to the patient to indicate the amount of pain. Measurements with the VAS will be performed only once per session. The average of these numbers will be recorded and the data will be analyzed.</i_keyword>
      <i_keyword>Control group: quadrant receiving Benzocaine as local anesthesia before injection = with a cotton swab on one side of the jaw benzocaine (20% benzocaine gel from Master dent) will be applied by the injector. Injection will be done 5 minutes after local anesthesia with 2% lidocaine (manufactured by Daru Pakhsh) with a 30 gauge needle (manufactured by DENJECT) in a 3 mm area of ​​the free gingival margin and that the needle's bevel is facing the bone, and the needle goes inside the tissue till it is in contact with bone. The injection is given to achieve palatal anesthesia. After the injection, the VAS scale is shown to the patient to indicate the amount of pain. Measurements with the VAS will be performed only once per session. The average of these numbers will be recorded and the data will be analyzed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain after needle insertion before palatal anesthesia injection. Timepoint: 5 minutes after applying the local anesthetic cream. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-12</approval_date>
        <contact_name>Ethics committee of Mazandran University of Medical Sciences</contact_name>
        <contact_address>Deputy of Research and Technology, Moallem Square, Sari Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
